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Previous applications of microarray technology for cancer research have mostly focused on identifying genes that are diﬀerentially
expressed between a particular cancer and normal cells. In a biological system, genes perform diﬀerent molecular functions and
regulate various biological processes via interactions with other genes thus forming a variety of complex networks. Therefore, it is
critical to understand the relationship (e.g., interactions) between genes across diﬀerent types of cancer in order to gain insights
into the molecular mechanisms of cancer. Here we propose an integrative method based on the bootstrapping Kolmogorov-
Smirnov test and a large set of microarray data produced with various types of cancer to discover common molecular changes
in cells from normal state to cancerous state. We evaluate our method using three key pathways related to cancer and demonstrate
that it is capable of ﬁnding meaningful alterations in gene relations.
Copyright © 2009 Bing Han et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Microarray technology, monitoring mRNA abundance of
tens of thousands of genes simultaneously, provides an
eﬃcient tool to characterize a cell at the molecular level. It
has been applied to a variety of research areas, ranging from
biomarker detection [1, 2] to gene regulatory networks [3–
5] and cancer classiﬁcation [6–8]. When applied to cancer
research, microarray technology typically measures gene
expressions of cancer and normal tissues or diﬀerent types
of cancer. One important area in microarray-based cancer
research is to identify genes that are diﬀerentially expressed
betweencancerousandnormalcellsandtodiscoverdiagnos-
tic and prognostic signatures in order to predict therapeutic
responses. Over the years, many statistical methods for the
identiﬁcation of diﬀerentially expressed genes have been
developed, and most of them focused on the expression
analysis of individual genes [9–15]. However, the simple list
of individual diﬀerentially expressed genes can only tell us
which genes are altered by biological diﬀerences between
diﬀerentcelltypesand/orstates.Itcannotexplainthereasons
for the signiﬁcant alterations in gene expression levels and
the eﬀects of such changes on other genes’ activities. It is well
known that in a biological system genes interact with each
other forming various biological pathways in order to carry
out a multitude of biological processes. To better understand
the roles of these diﬀerentially expressed genes and their
interactions in a complex biological system, a comprehensive
pathwayanalysisisneeded.Sincetheidentiﬁcationofbiolog-
icalpathwaysissigniﬁcantlyinﬂuencedbythosediﬀerentially
expressed genes from diﬀerent datasets or diﬀerent statistical
methods [16, 17], we reason here that an integration of
multiple cancer microarray datasets and identiﬁcation of the
most common pathways from these data would reveal key
relationships between crucial genes in carcinogenesis. Our
focus on the interactions and pathways of cancer-related
genes is important since changes in gene relations and key
pathways are more relevant to carcinogenesis than individual
genes alone.
Several statistical methods have been proposed for
the analysis of diﬀerential gene coexpression patterns. Li
[18]o b s e r v e dd i ﬀerences of gene coexpression patterns in
diﬀerent cellular states and attributed these changes in gene
coexpression patterns to some third set of inﬂuential genes.2 Journal of Biomedicine and Biotechnology
Lai et al. [19] proposed a similar method to identify diﬀer-
ential gene-gene coexpression patterns in cells from normal
state to cancerous state. However, these methods often
perform the analyses on one single microarray dataset and
typicallygenerateunreliableresults;theresultsfromdiﬀerent
microarray datasets and various statistical methods could
hardly overlap using these methods [20, 21]. Therefore, the
conﬁdence level for discoveries based on these methods is
low. Furthermore, these methods fail to grasp the common
molecular changes in cells transitioning from a normal
state to the cancerous state. Choi et al. [22] introduced a
model to ﬁnd diﬀerential gene coexpression patterns related
to cancer by combining independent datasets for diﬀerent
cancers. They used a model similar to the t-test, which only
considered the mean and variance of two groups of samples.
It is well known that traditional t-test has two disadvantages
formicroarraydataanalysis:ﬁrst,itassumesthatthedatasets
under analysis have a normal distribution, which is usually
violated in microarray datasets; second, if the number of
genes is large and the number of samples is small, some of
thestandarddeviationswillbeextremelysmall,andtherefore
the test statistics will be very high, which may lead to a
signiﬁcant bias. Nonparametric statistical test methods, such
as the K-S test, require fewer assumptions for the data and
may be preferred, especially, when the number of samples is
small.
In this paper, we propose a novel method to detect the
diﬀerentially changed gene relations in cancer versus normal
tissues. We collect 36 datasets across diﬀerent microarray
platformsandfromvarioustypesofcancer.These36datasets
contain both normal and tumor samples, which can subse-
quently yield two Pearson correlation coeﬃcient vectors for
every gene pair, one for normal samples and the other for
tumor samples. We then perform a bootstrapping K-S test
to identify some diﬀerentially changed gene relations. Finally
weverifyourresultswiththreekeypathwaysrelatedtocancer
and demonstrate that our method can ﬁnd some meaningful
a l t e r a t i o n so fg e n er e l a t i o n s .
2.MaterialsandMethods
2.1. Microarray Datasets. We collected 36 microarray
datasets from NCBI (Gene Expression Omnibus GEO) [23].
As shown in Table 1, these microarray datasets contain both
normal and tumor samples across 21 diﬀerent types of
cancer, and their platforms come from one of the three
platforms: GPL570 (Aﬀymetrix GeneChip Human Genome
U133 Plus 2.0 Array), GPL96 (Aﬀymetrix GeneChip
Human Genome U133 Array Set HG-U133A), and GPL91
(Aﬀymetrix GeneChip Human Genome U95 Version Set
HG-U95A). We divided every dataset into two expression
data matrices: one matrix includes all normal samples, and
the other includes all tumor samples. To integrate multiple
microarray datasets across diﬀerent platforms, we mapped
each probe in diﬀerent platforms to a unique Entrez Gene ID
or a unique UniGene symbol. For genes with more than one
probe in one platform, we chose the probe with the highest
mean expression value.
2.2. Cancer-Associated Pathways and Extended Gene Net-
works. We applied our method to analyze three cancer-
associated pathways. These pathways are related to three
common traits in most and perhaps all types of human
cancer: self-suﬃciency in growth signals, insensitivity to
antigrowth signals, and evading programmed cell death
(apoptosis) [24]. In fact, Hanahan and Weinberg have
already identiﬁed some signaling pathways to demonstrate
the capabilities cancer cells acquire during tumor develop-
ment in [24]. We extended these signaling pathways to three
relatively complete and larger cancer-associated pathways
(antigrowth signaling, apoptosis, and growth signaling path-
ways) from the cell cycle pathway, the apoptosis pathway
and the MAPK pathway in KEGG [25]. We used these three
pathways (i.e., cell cycle, apoptosis, and MAPK pathways) as
our seeds and the genes in these pathways as our seed genes.
Next we constructed three gene networks corresponding to
the three cancer-associated pathways from HPRD (Human
Proteins Reference Database, http://www.hprd.org/)a n d
TRANSFAC [26] based on seed genes and their interacting
partners. We downloaded the protein-protein interaction
(PPI) data released by HPRD on September 1, 2007. This
PPI dataset contains 37107 human binary protein-protein
interactions whose supporting experiments are indicated as
in vivo, in vitro, or yeast two-hybrid. We also collected 1042
transcription factor-target gene relations on human species
fromTRANSFAC.Soourgenenetworksincludedseedgenes,
protein interaction partners, and transcription factors (TFs)
of seed genes or target genes for which seed genes served as
their TFs.
2.3. Detecting Diﬀerential Relations by Bootstrapping K-S
Test. We used the Kolmogorov-Smirnov test (K-S test) to
determine whether the distributions of values in two datasets
diﬀered signiﬁcantly. The two-sample K-S test is the most
useful for comparing two samples because it is nonparamet-
ric and distribution-free [27]. The null hypothesis for this
testisthattwodatasetsaredrawnfromthesamedistribution.
The alternative hypothesis is that they are drawn from
diﬀerent distributions.
For n i.i.d samples X1,...,Xn with some unknown dis-
tribution, we can deﬁne an empirical distribution function
by
Sn(x) =
⎧
⎪ ⎪ ⎪ ⎪ ⎪ ⎨
⎪ ⎪ ⎪ ⎪ ⎪ ⎩
0, if x<X (1),
k
n
,i f X(k) ≤ x<X (k+1)
1, if x ≥ X(n),
for k = 1,2,...,n −1,
(1)
where X1,...,Xn are ordered from the smallest to the
largest value. The Kolmogorov-Smirnov statistic for a given
function S(x)i s
Dn = max
x
|Sn (x) −S(x)|. (2)
Dn will converge to 0 if the sample comes from distribution
S(x)[ 27]. Moreover, the cumulative distribution function ofJournal of Biomedicine and Biotechnology 3
Table 1: List of 36 microarray datasets.
Series ID in GEO Cancer type
Numbers
of normal
samples
Numbers
of tumor
samples
Numbers
of genes
Platform
ID in GEO
GSE3744 Breast cancer 7 40 54681 GPL570
GSE5764 Breast cancer 20 10 54681 GPL570
GSE7904 Breast cancer 19 43 54681 GPL570
GSE3678 Thyroid cancer 7 7 54681 GPL570
GSE3467 Thyroid cancer 9 9 54681 GPL570
GSE8977 Breast cancer 15 7 54681 GPL570
GSE8671 Colorectal cancer 32 32 54681 GPL570
GSE4290 Glioma 23 157 54681 GPL570
GSE4183 Colorectal cancer 8 30 54681 GPL570
GSE4107 Colorectal cancer 10 12 54681 GPL570
GSE8514 Aldosterone-producing adenoma 5 10 54681 GPL570
GSE6791 Cervical cancer 8 20 54681 GPL570
GSE6791 Head and neck cancer 18 38 54681 GPL570
GSE6338 Lymphoma 20 40 54681 GPL570
GSE5563 Vulvar intraepithelial neoplasia 9 9 54681 GPL570
GSE6004 Thyroid Cancer 4 14 54681 GPL570
GSE2549 Malignant pleural mesothelioma 10 44 22283 GPL96
GSE781 Kidney cancer 9 8 22283 GPL96
GSE7670 Lung cancer 27 27 22283 GPL96
GSE6344 Kidney cancer 10 10 22283 GPL96
GSE1542 Pancreatic ductal carcinoma 25 24 22283 GPL96
GSE6883 Breast cancer 6 6 22283 GPL96
GSE2724 Uterine ﬁbroid 11 7 22283 GPL96
GSE2503 Skin cancer 6 5 22283 GPL96
GSE3268 Lung cancer 5 5 22283 GPL96
GSE9476 Acute myeloid leukemia 38 26 22283 GPL96
GSE6008 Ovarian tumor 4 99 22283 GPL96
GSE6477 Multiple myeloma 12 150 22283 GPL96
GSE4115 Lung Cancer 90 97 22283 GPL96
GSE3167 Bladder cancer 14 46 22283 GPL96
GSE2514 Pulmonary adenocarcinoma 19 20 12651 GPL91
GSE6631 Head and neck cancer 22 22 12651 GPL91
GSE6604 Prostate tumor 18 25 12651 GPL91
GSE6605
GSE6606 Prostate tumor 63 65 12651 GPL91
GSE6608
GSE2379 Head and neck cancer 4 34 12651 GPL91
GSE1987 Lung Cancer 9 28 12651 GPL91
Kolmogorov distribution is
K (x) = 1 −2
∞  
i=1
(−1)
i−1e
−2i2x2
=
√
2π
x
∞  
i=1
e
−(2i−1)
2 π2/(8x2 ).
(3)
It is easy to prove that
√
nDn =
√
nmaxx|Sn(x) − S(x)| will
converge to the Kolmogorov distribution [27]. Therefore if
√
nDn >K α = Pr(K ≤ Kα) = 1 − α, the null hypothesis for
the Kolmogorov-Smirnov test will be rejected at level α.
For the case of determining whether the distributions
of two data vectors diﬀer signiﬁcantly, the Kolmogorov-
Smirnov statistic is
Dn,m = max
x
|Sn(x) −Sm(x)|,( 4 )4 Journal of Biomedicine and Biotechnology
and the null hypothesis will be rejected at level α if
 
nm
n+m
Dn,m >K α. (5)
The P-value from the K-S test can measure the conﬁdence
of the comparison results against the null hypothesis.
Obviously, the smaller the P-value, the more conﬁdent we
are of rejecting the null hypothesis.
Assume that we have n microarray datasets and a list of
m genes, we denote the expression data matrix for normal
samples as
Nk =
⎛
⎜ ⎜ ⎜ ⎜ ⎜ ⎜
⎝
Xk
11 Xk
12 ··· Xk
1p
Xk
21 Xk
22 ··· Xk
2p
....
Xk
m1 Xk
m2 ··· Xk
mp
⎞
⎟ ⎟ ⎟ ⎟ ⎟ ⎟
⎠
k = 1,...,n,( 6 )
and the expression data matrix for tumor samples as
Tl =
⎛
⎜ ⎜ ⎜ ⎜ ⎜ ⎜
⎝
Yl
11 Yl
12 ··· Yl
1q
Yl
21 Yl
22 ··· Yl
2q
....
Yl
m1 Yl
m2 ··· Yl
mq
⎞
⎟ ⎟ ⎟ ⎟ ⎟ ⎟
⎠
l = 1,...,n,( 7 )
where p(k) is the number of normal samples in the kth
dataset, and q(l) is the number of tumor samples in the lth
dataset.
For these two types of expression data matrices, each row
representsonegene,andeachcolumnrepresentsonesample.
The correlation coeﬃcient for gene i and gene j from the kth
normal sample can be calculated by
NPCk
ij =
 p
a=1
 
Xk
ia −X
k
i
  
Xk
ja − X
k
j
 
  p
a=1
 
Xk
ia −X
k
i
 2
  p
a=1
 
Xk
ja −X
k
j
 2,( 8 )
where X
k
i is the average value of expression levels for gene
i.T h ec o r r e l a t i o nc o e ﬃcient for every gene pair from tumor
samples can be calculated similarly.
We use the bootstrapping K-S test to detect some gene
r e l a t i o n sw i t hd i ﬀerent PC (Pearson coeﬃcient) distribu-
tions. The bootstrapping method generates N bootstrapping
samples NPC and TPC by repeatedly sampling with replace-
ment from the original NPCij and TPCij (e.g., Step 4),
respectively. It can give us an empirical distribution of P-
value θ, with which, we can estimate the probability that
the distribution of two PC vectors are diﬀerent. In our
computational experiment, for a gene pair, if its value of
Pr(θ<0.05) was larger than 0.8, we considered it as a pair
of genes with the correlation relation signiﬁcantly diﬀerent
between normal and cancer cells.
Our method can be described as follows.
Step 1. Compute n correlation coeﬃcient Matrices
NPC1–NPCn from the normal samples in n datasets
for every gene pairs. For example, NPC1 is an m × m
Matrix from normal samples in the ﬁrst dataset, and NPC1
ij
represents the correlation coeﬃcient between gene i,a n d
gene j.
Step 2. Compute n correlation coeﬃcient Matrices
TPC1–TPCn from the tumor samples in the n datasets
for every gene pair.
Step 3. For every gene pair (gene i and gene j), let
NPCij =
 
NPC1
ij NPC2
ij NPC3
ij ··· NPCn
ij
 
,
TPCij =
 
TPC1
ij TPC2
ij TPC3
ij ··· TPCn
ij
 
,
(9)
Step 4. Perform the following (N is the number of samples
we will generate using bootstrapping).
for k = 1t oN
Do generate bootstrap samples NPC and TPC from
NPCij and TPCij,r e s p e c t i v e l y .
θk = P-value of K-S test on NPC and TPC.
End-for
Output Pr(θ<0.05) =  (θ<0.05)/N.
3. ExperimentalResults
Inthissection,weappliedthebootstrappingK-Stestmethod
to analyze three cancer related pathways.
3.1. Antigrowth Signaling Pathway. Antigrowth signals can
control proliferation in normal samples. Cancer cells have
the ability to evade these antiproliferation signals. In the
antigrowth signaling pathway, transforming growth factor
beta (TGFβ) initiates this pathway by binding to two TGFβ
receptors, Tgfbr1 and Tgfbr2. These two activated Tgfβ
receptors can phosphorylate Smad2, Smad3, and Smad4
[28]. The SMAD family proteins then transduce antigrowth
signals to the cell cycle inhibitors p21, p16, p27, and
p15, which can inhibit the action of cyclin-CDK complex.
The cyclin-CDK complex can phosphorylate RB and make
RB dissociate from the E2F/RB complex to liberate E2F
to activate the cell cycle procession from G1 to S phase
(Figure 1(a)).
There are 19 genes in the antigrowth signaling pathway
(Figure 1(a)). We found 689 unique genes related to these 19
genes from TRANSFAC and HPRD. Among these 708 genes,
there were 4215 paired gene interactions, among which
the correlation relations of 47 gene pairs were identiﬁed
as signiﬁcantly changed between normal and cancer cells.
Among these 47 relations, we detected a cluster around
SMAD family proteins which contained 15 relations with
diﬀerent distributions between normal samples and tumor
samples (Figure 1(b)). Most of them came from large-
scale protein-protein interaction experiments without the
associatedmolecularfunction.Forexample,(Smad1–Arl4d),
(RHOD–Smad2), and (WEE1–Smad3) in [29], (PAPOLA–
Smad2), (SNRP70–Smad5), (GPNMB–Smad4), (PSMD11–
Smad3), and (Smad9–MBD1) in [30], and (EWSR1–Smad4)
in [31], all of them were detected based on large-scale
protein-protein interaction experiments without annotationJournal of Biomedicine and Biotechnology 5
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Figure 1: Antigrowth signaling pathway and cluster around SMAD proteins. (a) Antigrowth signaling pathway. Nodes and edges represent
human proteins and protein-protein interactions, respectively. Edges with direction represent a regulatory relation. → means an activating
relation and,   means an inhibitory relation. (b) Cluster around smads. Red edges represent diﬀerentially changed relations. Blue edges
represent unchanged relations. Red nodes represent tumor suppressor genes, and green nodes represent oncogenes.
of molecular function. Our results indicate that although
their associated functions and internal mechanisms are still
unclear, these gene pairs are related to the TGFβ-SMAD
signaling pathway, and the relation between the two genes
in each pair is signiﬁcantly diﬀerent in cancer and normal
cells. Additionally, we identiﬁed some diﬀerentially changed
relations with known molecular functions as follows:
(1) MAGI2 (a.k.a. ARIP1)–Smad3. MAGI2 (ARIP1) can
interact with Smad3, and overexpression of ARIP1
can signiﬁcantly suppress Smad3-induced transcrip-
tional activity [32]. We validated this from the
boxplotforMAGI2(ARIP1)–Smad3(Figure 2(a)).In
normalsamples,MAGI2(ARIP1)andSmad3showed
a high positive correlation, while they had a high
negative correlation in tumor samples.
(2) EWSR1–Smad4. Although the experiment type of
the interaction between EWSR1 and Smad4 is yeast
two-hybrid [31], mutations in EWSR1 are known
to cause Ewing sarcoma and other members of the6 Journal of Biomedicine and Biotechnology
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Figure 2: (a) Boxplot for MAGI2 (ARIP1)–Smad3. Pr(θ<0.05) = 0.986. (b) Boxplot for EWSR1–Smad4. Pr(θ<0.05) = 0.954. (c) Boxplot
for TRAP1–TgfbetaR2. Pr(θ<0.05) = 0.944.
Ewing family of tumors [33]. From the boxplot for
EWSR1–Smad4, we found that the third quartile
is the densest part of the whole distribution for
both normal and tumor samples. The third quartile
for normal samples showed a positive correlation
whereas that for tumor samples showed a negative
correlation (Figure 2(b)). Therefore, we suspect that
EWSR1 can suppress the activity of Smad4 in tumor
samples.
(3) TRAP1–Tgfbr2. TRAP1 has been shown to bind to
TGFβ receptors and play a role in TGFβ signaling
pathway. TRAP1 can interact with Smad4 and aﬀect
the SMAD-mediated signal transduction pathway.
Mutant TRAP1 can prevent the formation of the
Smad2–Smad4 complex to inhibit the TGFβ Signal-
ing pathway [34]. In the boxplot for TRAP1–Tgfbr2
(Figure 2(c)), the densest quartile for tumor samples
showed a high negative correlation.
3.2. Apoptosis Pathway. Cancer cells have the ability to
evade programmed cell death or apoptosis. TNFα,F A S L ,
TRAIL, and other genes can initiate apoptosis by bind-
ing to their receptors such as TNFR1, FAS, and TRAIL-
R. Many apoptosis signals induce mitochondrial changes.
Mitochondria can help transduce the apoptosis signals by
releasingcytochromeC(Cytc),apotentcatalystofapoptosis.
There are two diﬀerent Bcl-2 family members: proapoptotic
members (Bid, BAD) and antiapoptotic members (Bcl-2,
Bcl-xl), which activate and inhibit, respectively, the release of
Cytc. Finally, two key caspases (Casp8 and Casp9) activate
other downstream caspases that perform the cascading
events of cell death (Figure 3(a)).
In our results, we detected 33 relations with diﬀerent
distributions in the apoptosis pathway, and some are sup-
ported by existing experimental evidence. Examples include
(Figure 3(b)) the following:
(1) PUMA–Bcl-XL (BCL2L1). PUMA can interact with
Bcl-XL and meanwhile PUMA can also neutralize
and antagonize all the Bcl-2-like proteins [35].
From the boxplot for PUMA–Bcl-XL, we can ﬁnd
that Bcl-XL, and PUMA showed a higher negative
correlation in normal samples than in tumor samples
(Figure 4(a)).
(2) AKT1–BAD. Active forms of Akt can phosphorylate
BAD in vivo and in vitro to prevent it from promot-
ingcelldeath[36].IntheboxplotforAKT1–BAD,the
ﬁrstquartile,thedensestquartilefornormalsamples,
showed a higher positive correlation than the secondJournal of Biomedicine and Biotechnology 7
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Figure 3: (a) Apoptosis pathway. (b) Diﬀerentially changed gene relations in apoptosis pathway. Red edges represent diﬀerentially changed
relations. Blue edges represent unchanged relations. Red nodes represent tumor suppressor genes, and green nodes represent oncogenes.
quartile,thedensestfortumorsamples(Figure 4(b)).
SowespeculatedthatAktcansuppressBAD’sactivity
in tumor samples.
(3) KRT18–TRADD. TRADD is a KRT18-interacting
protein. KRT18 may inactivate TRADD to prevent
interactions between TRADD and the activated
TNFR1 and thus aﬀect TNFα-induced apoptosis
[37]. In the boxplot for KRT18–TRADD, nor-
mal samples showed a higher positive correlation
(Figure 4(c)).
(4) TNFR1–RIPK1 (RIP). The interaction between the
death domain of TNFα receptor-1 (TNFR1) and
TRADD can trigger distinct signaling pathways lead-
ing to apoptosis. TRADD also interacts strongly with
another death domain protein; RIP and RIP plays
an important role in the TNF signaling cascades
leading to apoptosis [38]. In the boxplot for TNFR1–
RIPK1, TNFR1 and RIPK1 exhibited high positive
c o r r e l a t i o ni nn o r m a ls a m p l e s( Figure 4(d)).
(5) TNFR1–RASSF1. RASSF1A is a tumor suppressor
gene.ApoptosisinitiationbyTNFαorTRAILrecruits
RASSF1A and MAP-1 to form complexes. RASSF1A
and MAP-1 are the key links between death receptors
and the apoptotic machinery [39]. This was veriﬁed
by the Boxplot for TNFR1–RASSF1. In most normal
samples, these genes showed a high positive correla-
tion. In most tumor samples, they showed a zero or
negative correlation (Figure 4(e)).
(6) IAP–CASP9. Inhibitor of apoptosis (IAP) suppresses
the activities of caspases and inhibits diﬀerent apop-
totic pathways [40]. IAP and CASP9 showed a high
negative correlation in tumor samples (Figure 4(f)).8 Journal of Biomedicine and Biotechnology
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Figure 4: (a) Boxplot for PUMA–Bcl-XL(BCL2L1). Pr(θ<0.05) = 0.998. (b) Boxplot for AKT1–BAD. Pr(θ<0.05) = 0.859. (c) Boxplot
for KRT18–TRADD. Pr(θ<0.05) = 0.991.(d) Boxplot for TNFR1–RIPK1(RIP). Pr(θ<0.05) = 0.831. (e) Boxplot for TNFR1–RASSF1.
Pr(θ<0.05) = 0.946. (f) Boxplot for IAP–CASP9. Pr(θ<0.05) = 0.826.
Among the eight diﬀerential gene relations in Figure 3(b),
three of them were in the seed pathway: TRAIL-R→FADD,
IAP→CASP9, and AKT→BAD, which demonstrates the
eﬀectiveness of the proposed method.
3.3. Growth Signaling Pathway. Cancer cells have the ability
to produce their own growth promoting signals. EGF, TGFα,
and PDGF are activated and then bind to their receptors
to transduce the growth signals. The activated growth
factor receptors can in turn activate the SOS-Ras Raf Mapk
cascade. In the growth signal pathway (Figure 5), Ras, JUN,
and Fos are oncogenes.
We could ﬁnd 68 relations with diﬀerent distributions in
the growth signal pathway, and we discuss three relations as
follows:
(1) RASSF2–KRAS. Although diﬀerent forms of Ras are
frequently thought of as oncogenes, they also have
the ability to produce antigrowth eﬀects such as cellJournal of Biomedicine and Biotechnology 9
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Figure 6: (a) Boxplot for RASSF2–KRAS. Pr(θ<0.05) = 0.983. (b) Boxplot for MAZ–MYC. Pr(θ<0.05) = 0.833. (c) Boxplot for PLSCR1–
EGFR. Pr(θ<0.05) = 0.963.10 Journal of Biomedicine and Biotechnology
cycle arrest, diﬀerentiation, and apoptosis. RASSF2
can bind directly to K-Ras. Moreover, RASSF2 can
inhibitthegrowthoftumorcells,andtheactivatedK-
Ras can enhance this ability [41]. This might be why
RASSF2 and RAS showed a high positive correlation
in normal samples in the boxplot (Figure 6(a)).
(2) MAZ–MYC. The MAZ family can increase the onco-
geneMYC’stranscriptionalactivity[42].Asexpected,
MAZ and MYC demonstrated a higher positive
c o r r e l a t i o ni nt u m o rs a m p l e s( Figure 6(b)).
(3) PLSCR1–EGFR. Activated epidermal growth factor
receptors (EGFRs) can both physically and func-
tionally interact with PLSCR1. In turn, PLSCR1 can
interact with Shc and thus accelerate the activation
of Src kinase through the EGF receptor, while Src
caninitiatesomeactivatingpathwayfortheoncogene
JUN [43]. In the boxplot for PLSCR1–EGFR, the
densest quartile for normal samples showed a low
negative correlation, whereas the densest quartile for
tumor samples showed a low positive correlation
(Figure 6(c)).
4. Conclusion and Discussion
After several decades of cancer research, some details of the
underlying mechanisms of cancer at the gene level are still
unclear. In this paper, we propose an integrative method
based on the bootstrapping K-S test to evaluate a large
number of microarray datasets generated from 21 diﬀerent
types of cancer in order to identify gene pairs that have
diﬀerent relationships in normal versus cancer tissues. The
signiﬁcant alteration of gene relations can greatly extend
our understanding of the molecular mechanisms of human
cancer. In our method, we obviate the disadvantage of
the traditional t-test, which only considers the mean and
variance of samples and fails in the analysis of microarray
data with small numbers of samples. Instead of the t-test,
we propose the use of the bootstrapping K-S test method
to detect gene pairs with diﬀerent distributions of Pearson
correlation coeﬃcient values in normal and tumor samples.
The experimental results demonstrated that our method
could ﬁnd meaningful alterations in gene relations and
opened a potential door for further cancer research.
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